uniQure N.V. Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years
uniQure N.V. (QURE) had Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years of $6.14 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Expected Amounts › Defined Benefit Plan, Expected Future Benefit Payment
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter · last filed 2026-03-02
- 2025-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $6.14M.
- 2024-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $4.75M.
- 2023-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $4.99M.
| Period end | Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years |
|---|---|
| 2025-12-31 | $6.14M 10-K · filed 2026-03-02 |
| 2024-12-31 | $4.75M 10-K · filed 2026-03-02 |
| 2023-12-31 | $4.99M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |